Result: Risk Minimisation Materials for medicines starting with the letter T

Tarceva

Roche Products Limited

Tarceva (erlotinib): Educational Material for Health Care Professionals for Dosing Guidelines and Interstitial Lung Disease (ILD) Awareness and Management Strategies

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

For Healthcare Professionals

Tarivid

SANOFI

Tarivid Tablets and Tarivid Liquid- DHPC Letter - Participants in DHPC on products containing fluoroquinolone antibiotics and the risk of aortic aneurysm & dissection

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Tasmar

Meda Pharmaceuticals

Tasmar Patient Diary

To help you keep track of your appointments for liver function tests during the first year

Tecentriq

Roche Products Limited

Tecentriq (atezolizumab) Important Safety Information to Minimise the Risks of Immune-Related Adverse Reactions for Healthcare Professionals

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

For Healthcare Professionals

Tecentriq (atezolizumab) Patient Alert Card

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

Tenofovir

Generics UK T/A Mylan

Healthcare Professional Renal Management Ruler for patients taking Tenofovir Disoproxil for the Treatment of Hepatitis B

Renal Management and Dose Adjustment Advice for Healthcare Professionals with Adult Patients Receiving Tenofovir Disoproxil for the Treatment of Hepatitis B

For Healthcare Professionals

Healthcare Professional Renal Management Ruler for patients taking Tenofovir Disoproxil for the Treatment of HIV

Renal Management and Dose Adjustment Advice for Healthcare Professionals with Adult Patients Receiving Tenofovir Disoproxil for the Treatment of HIV

For Healthcare Professionals

Tenofovir HBV Paediactrics Brochure

Tenofovir HBV Paediactrics Brochure advice for HCPs

For Healthcare Professionals

Tenofovir HIV Paediactrics Brochure

Tenofovir HIV Paediactrics Brochure advice for HCPs

For Healthcare Professionals

Glenmark Pharmaceuticals Europe Ltd

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescent with HIV-1

HIV-1 Renal & bone effects education brochure - children and adolescent

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Chronic Hepatitis B education brochure – adolescent children

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Chronic Hepatitis B education brochure – adults

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

HIV renal education brochure – adults

For Healthcare Professionals

Accord Healthcare Limited

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1. If you require further information about Tenofovir and hard copies of the material please contact medinfo@accord-healthcare.com. If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B. If you require further information about Tenofovir and hard copies of the material please contact medinfo@accord-healthcare.com. If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B. If you require further information about Tenofovir and hard copies of the material please contact medinfo@accord-healthcare.com. If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV. If you require further information about Tenofovir and hard copies of the material please contact medinfo@accord-healthcare.com. If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Dr. Reddy's Laboratories (UK) Ltd

Renal and Bone Effects Risk Minimisation Material: Tenofovir Disoproxil for Children and Adolescents with HIV-1

HIV-1 Renal & bone effects education brochure - children

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

HBV renal education brochure - children

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

HBV renal education brochure – adults

For Healthcare Professionals

Renal Risk Minimisation Material: Tenofovir Disoproxil for Adults with HIV

HIV renal education brochure - adults

For Healthcare Professionals

Zentiva

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

Submission of Risk Minimisation Materials (coordinated by BGMA) to agency – minimising the risks of renal and bone effects for children and adolescents with HIV

RENAL RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR ADULTS WITH HIV

Submission of Risk Minimisation Materials (coordinated by BGMA) to agency - minimising the risks for Adults with HIV

Tenofovir disoproxil - Renal Risk Minimisation Adults with Chronic Hepatitis B

For hard copies please contact our medical information department on 0800 090 2408 or email UKMedInfo@zentiva.com

Tenofovir disoproxil - Renal Risk Minimisation for adolescent children

For hard copies please contact our medical information department on 0800 090 2408 or email UKMedInfo@zentiva.com

Lupin Healthcare (UK) Ltd

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Tenofovir disoproxil Lupin 245 mg film-coated tablets

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV1

Tenofovir disoproxil Lupin 245 mg film-coated tablets

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

Toctino

Stiefel

Toctino Acknowledgement Form for Female Patients

Acknowledgement Form for Female Patients

For Healthcare Professionals

Toctino Dear Healthcare Professional Letter

This letter contains details of the requirements of the Pregnancy Prevention Programme

For Healthcare Professionals

Toctino Doctors checklist for Prescribing to Female Patients

This checklist should be used in conjunction with other Pregnancy Prevention Programme materials

For Healthcare Professionals

Toctino Guidance for Doctors and Pharmacists

Guidance for doctors prescribing Toctino and dispensing requirements for pharmacists

For Healthcare Professionals

Toctino Information About Contraception

Information booklet on contraception requirements for patients being prescribed Toctino

Toctino Patient Information Brochure

This brochure contains important information about treatment with Toctino, and the risk of possible birth defects. It should be read carefully before taking Toctino.

Toujeo

SANOFI

Toujeo Solostar prefilled pen (insulin glargine 300 units/ml) Guide for Healthcare Professionals

HCP risk minimisation educational leaflet for 300 units/ml solution for injection in a pre-filled pen. For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Toujeo Solostar prefilled pen (insulin glargine 300 units/ml) Guide for patients and/or carers

Patient and Caregiver risk minimisation educational leaflet for Toujeo 300 units/ml solution for injection in a pre-filled pen. For hard copies please contact our medical information department at 01483 505515 or email uk-medicalinformation@sanofi.com .

Tresiba

Novo Nordisk Limited

Tresiba® 100U and 200U FlexTouch® correct use of Tresiba® (insulin degludec)-to-minimise-medication-errors

Direct Healthcare Professional Communication for Tresiba® 100U and 200U FlexTouch® correct use of Tresiba® (insulin degludec) to minimise medication errors

For Healthcare Professionals

Triumeq

ViiV Healthcare UK Ltd

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Trizivir

ViiV Healthcare UK Ltd

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Trobalt

GlaxoSmithKline UK

Trobalt Physician's Guide

A guidance document for Healthcare Professionals prior to prescribing Trobalt to patients

For Healthcare Professionals

Truvada

Gilead Sciences Ltd

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Checklist For Prescribers

Checklist For Prescribers from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection

For Healthcare Professionals

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Patient Leaflet

Patient Leaflet from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection. It contains Important Information About Truvada® (emtricitabine/tenofovir disoproxil fumarate) to Reduce the Risk of Getting Human Immunodeficiency Virus (HIV) Infection for individuals who have been prescribed Truvada® for Pre-Exposure Prophylaxis (PrEP)

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Prescribers Leaflet

Important Safety Information for Prescribers About Truvada® (emtricitabine/tenofovir disoproxil fumarate) for a Pre-exposure Prophylaxis (PrEP) Indication

For Healthcare Professionals

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Reminder Card

Reminder Card for patients from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection.

Truxima

Napp Pharmaceuticals Limited

Truxima Administration Route

IV Infusion Only

For Healthcare Professionals

Truxima Patient Alert Card

Patient Alert Card

Truxima Patient Information

Information for Patients

Truxima Safety Sheet

Information for Healthcare Professionals

For Healthcare Professionals

Tysabri

Biogen Idec Ltd

Patient Alert Card

This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). Hard copies can be requested by contacting Biogen at MedInfoUKI@biogen.com or by telephone on 0800 008 7401.

Physician Information and Management Guidelines for Multiple Sclerosis Patients on TYSABRI Therapy

This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.

For Healthcare Professionals

Treatment Continuation Form

This form should be read carefully before continuing TYSABRI treatment for more than 2 years.

Treatment Discontinuation Form

This form should be read carefully before discontinuing treatment with TYSABRI.

Treatment Initiation Form

This form should be read carefully before starting treatment with TYSABRI.